Preventing Glass Delamination: A Critical Quality Risk for Injectable Drug Packaging

Introduction

Glass delamination remains one of the most technically challenging and consequential quality failures in pharmaceutical packaging. For injectable drug products, the interaction between the glass container surface and the drug formulation can lead to the formation of microscopic glass flakes, known as “glass lamellae,” that detach from the inner surface and contaminate the drug solution. These particles pose direct patient safety risks, and regulatory agencies have increasingly scrutinized such failures in drug applications and post-market surveillance.

This article examines the root causes of glass delamination, the regulatory framework surrounding it, and the practical strategies that pharmaceutical manufacturers and packaging suppliers can adopt to mitigate risk.

What Is Glass Delamination?

Delamination is a surface-level phenomenon. Unlike glass fracture or breakage, which occurs through mechanical stress, delamination involves a chemical attack on the glass surface by the drug formulation. The inner surface of the glass container undergoes a hydrolysis reaction, leaching alkali and other glass-forming oxides from the silica network. Over time, a hydrated, silica-rich layer forms on the surface. Under certain conditions, this layer can separate from the bulk glass and flake off into the drug product.

The resulting particles are typically thin, plate-like lamellae that are often too small to be detected by visual inspection. This makes delamination particularly insidious: a container that appears visually acceptable may nonetheless be shedding glass particles into its contents throughout the product’s shelf life.

Root Causes and Contributing Factors

Delamination is not caused by a single variable but by the convergence of multiple factors. Drug formulation composition is a primary driver. High-pH formulations, formulations containing citrate or phosphate buffers, and products with high ionic strength are known to accelerate glass surface attack. Sodium-containing drugs and formulations that undergo terminal sterilization at elevated temperatures are also at elevated risk.

The glass itself plays a critical role. Glass tubing produced with improper melting or drawing conditions can have a heterogeneous surface composition, with regions of elevated alkali content. The “fire-polishing” or flame treatment that containers undergo during conversion can also alter the surface chemistry if not precisely controlled. Interior surface hydrolytic resistance, the property measured by USP <660> testing, serves as a primary indicator of a glass container’s ability to resist this chemical attack .

Processing conditions during filling also contribute. Exposure to high-temperature depyrogenation tunnels, repeated autoclaving cycles, and long-term storage at elevated temperatures can all accelerate the progression from surface hydration to delamination.

Regulatory Expectations

The FDA has taken a direct interest in glass delamination since the early 2010s, when several product recalls and drug application deficiencies highlighted the issue. In response, USP developed <1660> “Evaluation of the Inner Surface Durability of Glass Containers,” which provides a framework for assessing delamination risk. This chapter is closely tied to USP <660> and emphasizes predictive screening before a product enters clinical or commercial production .

The 2023 revisions to USP <660> moved the standard from a composition-based to a performance-based classification. Type I borosilicate glass is no longer defined solely by its chemical composition but by its demonstrated hydrolytic resistance performance . This shift was driven in part by FDA recommendations to allow for new glass compositions that perform equivalently to traditional borosilicate.

For manufacturers seeking US or EU market approval, demonstrating control over delamination risk is now an expected component of the container closure system qualification. Extractables and leachables (E&L) studies, performed in accordance with USP <1663> and <1664>, are frequently requested by regulators to support the safety assessment of glass containers in contact with drug products .

Mitigation Strategies

Formulation and Container Compatibility Assessment. The most effective approach is to assess compatibility before locking in a container specification. Accelerated stability studies that expose the drug product to the intended glass container at elevated temperatures can reveal early signs of surface attack. If incompatibility is detected, alternative glass types—such as high borosilicate glass with a higher B₂O₃ content—may be required.

Supplier Qualification and Raw Material Control. Not all Type I borosilicate glass is equivalent. Variations in boron content, aluminum content, and melting practices can produce measurable differences in delamination resistance. OCTRD notes that “fake borosilicate” glass with insufficient B₂O₃ content can lead to high leaching rates and drug degradation . Pharmaceutical manufacturers should require suppliers to provide batch-specific hydrolytic resistance data and, where feasible, conduct periodic on-site quality audits.

Surface Treatment and Container Design. The interior surface condition of the glass container directly affects delamination resistance. Suppliers can employ controlled fire-polishing or chemical surface treatments to produce a more homogeneous, hydrolysis-resistant inner surface. Container geometry also matters: areas of high stress or sharp transitions in wall thickness can create localized regions of elevated chemical reactivity.

Process Optimization. Depyrogenation tunnel conditions should be validated to avoid excessive heat exposure that can degrade the glass surface. Similarly, the number and duration of autoclave cycles should be minimized to the extent compatible with sterility assurance.

Conclusion

Glass delamination is a complex, multi-factorial phenomenon that requires a systematic approach to risk management. For pharmaceutical manufacturers, the key takeaway is that compatibility between drug formulation and glass container must be verified through testing, not assumed based on material classification alone. For packaging suppliers, the competitive advantage lies in controlling the variables that influence surface durability—glass composition, melting and drawing practices, and surface treatment—and in providing transparent, batch-specific performance data to support regulatory submissions.

---